Download PDF
Exp Clin Endocrinol Diabetes 2005; 113(7): 365-371
DOI: 10.1055/s-2005-865681
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

PGE1 Inhibits the Expression of PAI-1 mRNA Induced by TNF-α in Human Mesangial Cells

M. Kishida1 , M. Urakaze1 , M. Takata1 , Y. Nobata1 , N. Yamamoto1 , R. Temaru1 , A. Sato1 , K. Yamazaki1 , N. Nakamura2 , M. Kobayashi1
  • 1Toyama Medical and Pharmaceutical University, Faculty of Medicine, the First Department of Internal Medicine, Toyama-shi, Toyama, Japan
  • 2Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
Further Information

Publication History

Received: December 1, 2004 First decision: March 22, 2005

Accepted: April 13, 2005

Publication Date:
18 July 2005 (online)

Also available at
    Permissions and Reprints

Abstract

We examined the effect of PGE1 on the expression of plasminogen activator inhibitor-1 (PAI-1) mRNA induced by tumor necrosis factor-α (TNF-α) in human mesangial cells, because PAI-1 is one of major factors for the progression of glomerulosclerosis. The expression of PAI-1 mRNA was increased after stimulation with TNF-α, and it was diminished by pre-incubation with PGE1. Next, we examined the effect of PGE1 on the phosphorylation of mitogen activated protein kinase (MAPK) family and Akt. TNF-α activated the phosphorylation of p44/42 MAPK, p38 MAPK, SAPK/JNK and Akt in mesangial cells. PGE1 inhibited the TNF-α induced phosphorylation of SAPK/JNK and Akt, but not p44/42 MAPK and p38 MAPK. The TNF-α induced expression of PAI-1 mRNA was not affected by PD98059, an inhibitor of MEK, SB203580, an inhibitor of p38 MAPK, nor LY294002, an inhibitor of PI3 K. However, DMAP, an inhibitor of SAPK/JNK, inhibited the expression of PAI-1 mRNA, suggesting that the TNF-α induced expression of PAI-1 mRNA is regulated by the SAPK/JNK dependent pathway in human mesangial cells. By the incubation with H8, an inhibitor of PKA, the inhibitory effect of PGE1 on the expression of PAI-1 mRNA was abolished, suggesting that PGE1 inhibited the PAI-1 mRNA expression via the PKA pathway. Our results suggest that the inhibition of PAI-1 synthesis by PGE1 in human mesangial cells may have therapeutic implications for glomerulosclerosis such as occurs in diabetic nephropathy.

Key words

PGE1 - PAI-1 - TNF-α - human mesangial cells - SAPK/JNK

Reference

  • 1 Andreasen P A, George B, Lund L R, Riccio A, Stacey S N. Plasminogen activator inhibitors: hormonally regulated serpins.  Mol Cell Endocrinol. 1990;  68 1-19
    CrossrefPubMedGoogle Scholar
  • 2 Baricos W H, Cortez S L, El-Dahr S S, Schnaper H W. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.  Kidney Int. 1995;  47 1039-1047
    PubMedGoogle Scholar
  • 3 Boulton T G, Nye S H, Robbins D J, Ip N Y, Radziejewska E, Morgenbesser S D, DePinho R A, Panayotatos N, Cobb M H, Yancopoulos G D. ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF.  Cell. 1991;  65 663-675
    CrossrefPubMedGoogle Scholar
  • 4 Brenner B M, Cooper M E, de Zeeuw D. et al . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.  N Engl J Med. 2001;  345 861-869
    CrossrefPubMedGoogle Scholar
  • 5 Dell K, Bohler T, Gaedeke J. et al . Impact of PGE1 on cyclosporine A induced up-regulation of TGF-beta1, its receptors, and related matrix production in cultured mesangial cells.  Cytokine. 2003;  22 189-193
    CrossrefPubMedGoogle Scholar
  • 6 Denu J M, Zhou G, Wu L, Zhao R, Yuvaniyama J, Saper M A, Dixon J E. The purification and characterization of a human dual-specific protein tyrosine phosphatase.  J Biol Chem. 1995;  270 3796-3803
    CrossrefPubMedGoogle Scholar
  • 7 Derijard B, Hibi M, Wu I H, Barrett T, Su B, Deng T, Karin M, Davis R J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.  Cell. 1994;  76 1025-1037
    CrossrefPubMedGoogle Scholar
  • 8 Ding A H, Porteu F, Sanchez E, Nathan C F. Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents.  J Exp Med. 1990;  171 715-727
    CrossrefPubMedGoogle Scholar
  • 9 Dzurik R, Spustova V, Janekova K. The prevalence of insulin resistance in kidney disease patients before the development of renal failure.  Nephron. 1995;  69 281-285
    PubMedGoogle Scholar
  • 10 EUCLID study group . Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria.  Lancet. 1997;  349 1787-1791
    CrossrefPubMedGoogle Scholar
  • 11 Freshney N W, Rawlinson L, Guesdon F. et al . Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27.  Cell. 1994;  78 1039-1049
    CrossrefPubMedGoogle Scholar
  • 12 Groop L, Ekstrand A, Forsblom C, Widen E, Groop P H, Eriksson J. Insulin resistance, hypertension and microalbuminuria in patients with type II (non insulin-dependent) diabetes mellitus.  Diabetologia. 1993;  36 642-647
    CrossrefPubMedGoogle Scholar
  • 13 Han J, Lee J D, Bibbs L, Ulevitch R J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.  Science. 1994;  265 808-811
    PubMedGoogle Scholar
  • 14 Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy.  Kidney Int. 1991;  40 1007-1012
    PubMedGoogle Scholar
  • 15 Hirano T, Kashiwazaki K, Morimoto Y, Nagano S, Adachi M. Albuminuria is directly associated with increased plasma PAI-1 and factor levels in NIDDM patients.  Diabetes Res Clin Pract. 1997;  36 11-18
    CrossrefPubMedGoogle Scholar
  • 16 Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Kitamura T, Ogawa W, Yokoyama M. TNF-α induces protein synthesis through PI3-kinase-Akt/PKB pathway in cardiac myocytes.  Am J Physiol Heart Circ Physiol. 2001;  280 H1861-1868
    PubMedGoogle Scholar
  • 17 Hotamisligil G S. Molecular mechanisms of insulin resistance and the role of the adipocyte.  Int J Obes Relat Metab Disord. 2000;  24 (Suppl 4) S23-27
    CrossrefPubMedGoogle Scholar
  • 18 Itoh Y, Yasui T, Kakizawa H, Makino M, Fujisawa K, Kato T, Imamura S, Yamamoto K, Hishida H, Nakai A, Itoh M, Nagasaka A. The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors.  Prostaglandins Other Lipid Mediat. 2001;  66 221-234
    CrossrefPubMedGoogle Scholar
  • 19 Iwata M, Haruta T, Usui I. et al . Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-γ.  Diabetes. 2001;  50 1083-1092
    PubMedGoogle Scholar
  • 20 Katsuki A, Sumida Y, Murata K, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Gabazza E C, Adachi Y. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.  Diabetes Obes Metab. 2000;  2 189-191
    CrossrefPubMedGoogle Scholar
  • 21 Kreisberg J I, Ayo S H. The glomerular mesangium in diabetes mellitus.  Kidney Int. 1993;  43 109-113
    PubMedGoogle Scholar
  • 22 Kruithof E K. Plasminogen activator inhibitors - a review.  Enzyme. 1988;  40 113-121
    PubMedGoogle Scholar
  • 23 Kyriakis J M, Banerjee P, Nikolakaki E, Dai T, Rubie E A, Ahmad M F, Avruch J, Woodgett J R. The stress-activated protein kinase subfamily of c-Jun kinases.  Nature. 1994;  369 156-160
    CrossrefPubMedGoogle Scholar
  • 24 Lee J C, Laydon J T, McDonnell P C, Gallagher T F, Kumar S, Green D, McNulty D, Blumenthal M J, Heys J R, Landvatter S W. et al . A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.  Nature. 1994;  372 739-746
    CrossrefPubMedGoogle Scholar
  • 25 Lewis E J, Hunsicker L G, Bain R P. et al . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.  N Eng J Med. 1993;  329 1456-1462
    CrossrefPubMedGoogle Scholar
  • 26 Marino M W, Dunbar J D, Wu L W, Ngaiza J R, Han H M, Guo D, Matsushita M, Nairn A C, Zhang Y, Kolesnick R, Jaffe E A, Donner D B. Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine.  J Biol Chem. 1996;  271 28624-28629
    CrossrefPubMedGoogle Scholar
  • 27 Maschio G, Alberti D, Janin G. et al . Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.  N Eng J Med. 1996;  334 939-945
    CrossrefPubMedGoogle Scholar
  • 28 Mauer S M, Steffes M W, Ellis E N, Sutherland D ER, Brown D M, Goetz F C. Structural-functional relationships in diabetic nephropathy.  J Clin Invest. 1984;  74 1143-1155
    PubMedGoogle Scholar
  • 29 Meulders Q, He C J, Adida C, Peraldi M N, Schuleuning W D, Sraer J D, Rondeau E. Tumor necrosis factor α increases antifibrinolytic activity of cultured human mesangial cells.  Kidney Int. 1992;  42 327-334
    PubMedGoogle Scholar
  • 30 Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-α and insulin resistance in obese men with Type 2 diabetes mellitus.  Diabetes Res Clin Pract. 2001;  52 119-123
    CrossrefPubMedGoogle Scholar
  • 31 Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H. mRNA expression of growth factors in glomeruli from diabetic rats.  Diabetes. 1993;  42 450-456
    PubMedGoogle Scholar
  • 32 Nicholas S B, Kawano Y, Wakino S, Collins A R, Hsueh W A. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells.  Hypertension. 2001;  37 722-727
    PubMedGoogle Scholar
  • 33 Ninomiya Y, Arakawa M. Renal effects of prostaglandin E1 in type 2 (non-insulin-dependent) diabetic patients with subclinical nephropathy.  Diabetes Res. 1989;  10 129-134
    PubMedGoogle Scholar
  • 34 Niskanen L, Laakso M. Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellitus.  Metabolism. 1993;  42 1541-1545
    CrossrefPubMedGoogle Scholar
  • 35 Parving H H, Osterby R, Anderson P W, Hsueh W A. Brenner BM (ed) Brenner and Rector's The Kidney. 5th ed. Philadelphia; W. B. Saunders 1996: 1864-1883
    Google Scholar
  • 36 Peraldi M N, Rondeau E, Medcalf R L, Hagege J, Lacave R, Delarue F, Schleuning W D, Sraer J D. Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells.  Biochim Biophys Acta. 1992;  1134 189-196
    PubMedGoogle Scholar
  • 37 Rerolle J P, Hertig A, Nguyen G. et al . Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.  Kidney Int. 2000;  58 1841-1850
    CrossrefPubMedGoogle Scholar
  • 38 Pirart J. Why don't we teach and treat diabetic patients better?.  Diabetes Care. 1978;  1 139-140
    PubMedGoogle Scholar
  • 39 Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda A R. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins.  Cell. 1994;  78 1027-1037
    CrossrefPubMedGoogle Scholar
  • 40 Saksela O. Plasminogen activation and regulation of pericellular proteolysis.  Biochim Biophys Acta. 1985;  823 35-65
    PubMedGoogle Scholar
  • 41 Saksela O, Rifkin D B. Cell-associated plasminogen activation: regulation and physiological functions.  Annu Rev Cell Biol. 1988;  4 93
    CrossrefPubMedGoogle Scholar
  • 42 Sraer J D, Kanfer A, Rondeau E, Lacave R. Glomerular hemostasis in normal and pathologic conditions.  Adv Nephrol Necker Hosp. 1988;  17 27-55
    PubMedGoogle Scholar
  • 43 Suzuki M, Kanazawa A, Shiba M, Kojima H, Harano Y. Insulin resistance in diabetic microangiopathies.  J Diabetes Complications. 2000;  14 40-45
    CrossrefPubMedGoogle Scholar
  • 44 Takata M, Urakaze M, Temaru R, Yamazaki K, Nakamura N, Nobata Y, Kishida M, Sato A, Kobayashi M. Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.  Br J Pharmcol. 2001;  134 753-762
    PubMedGoogle Scholar
  • 45 Temaru R, Urakaze M, Sato A, Yamazaki K, Nakamura N, Kobayashi M. High glucose enhances the gene expression of interleukin-8 in human endothelial cells, but not in smooth muscle cells: possible role of interleukin-8 in diabetic macroangiopathy.  Diabetologia. 1997;  40 610-613
    CrossrefPubMedGoogle Scholar
  • 46 Tomooka S, Border W A, Marshall B C, Noble N A. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system.  Kidney Int. 1992;  42 1462-1469
    PubMedGoogle Scholar
  • 47 Tracey K J, Cerami A. Tumor necrosis factor, other cytokines and disease.  Annu Rev Cell Biol. 1993;  9 317-343
    CrossrefPubMedGoogle Scholar
  • 48 Vassalli J D, Sappino A P, Belin D. The plasminogen activator/plasmin system.  J Clin Invest. 1991;  88 1067-1072
    PubMedGoogle Scholar
  • 49 Wahab N A, Mason R M. Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture.  Biochem J. 1996;  320 777-783
    PubMedGoogle Scholar
  • 50 Werb Z, Mainardi C L, Vater B A, Harris Jr E D. Endogenous activation of latent collagenase by rheumatoid synovial cells.  N Engl J Med. 1977;  296 1017-1023
    PubMedGoogle Scholar
  • 51 Wirta O R, Pasternack A I, Mustonen J T, Koivula T A, Harmoinen A. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients.  Nephrol Dial Transplant. 1996;  11 449-456
    PubMedGoogle Scholar

MD, PhD Masaharu Urakaze

Toyama Medical and Pharmaceutical University
Faculty of Medicine
First Department of Internal Medicine

2630 Sugitani

Toyama-shi

Toyama, 930-0192

Japan

Phone: + 764347286

Fax: + 76 4 34 50 25

Email: murakaze@ms.toyama-mpu.ac.jp

      >